BOC Sciences is dedicated to developing high-performance nanocarriers for antibody-drug conjugates (ADCs). Leveraging profound expertise in chemical modification and nanoengineering, we have established an integrated development system encompassing multiple platforms, including lipid nanoparticles, polymeric nanoparticles, inorganic nanomaterials, and carbon nanoparticles. We offer not only customized carrier design, antibody conjugation, and intelligent release construction but also possess capabilities in pilot-scale production and GMP translation, fully supporting all stages from early research to commercialization. With a highly modular technical platform and stringent quality control, BOC Sciences provides customers with safe, stable, and controllable ADC nanodelivery solutions to accelerate clinical translation of precision-targeted therapeutics.
Nanocarrier particle size and distribution tend to fluctuate, affecting product stability. BOC Sciences employs microfluidics and precision process control to ensure batch consistency and structural controllability.
Non-specific conjugation between antibodies and carriers may generate impurities. We provide site-specific conjugation and click chemistry strategies to enhance conjugation uniformity and bioactivity.
Carriers are prone to rapid clearance, making precise release difficult. BOC Sciences constructs a variety of responsive structures to balance circulation stability and target sensitivity.
Multifunctional carrier designs are complex and time-consuming. Our modular platform rapidly assembles components, shortening development cycles and reducing costs.
BOC Sciences possesses a mature nanomaterial development platform capable of offering diverse nanocarrier solutions based on varying ADC structures and therapeutic needs. We develop mainstream types of nanoplatforms from multiple dimensions, including biocompatibility, drug-loading capacity, targeting potential, and in vivo stability of carrier materials:
In ADC nanocarrier systems, surface functionalization and antibody conjugation are key steps in achieving targeting, stability, and preservation of bioactivity. With extensive experience in bioconjugation chemistry, interface engineering, and antibody modification, BOC Sciences offers comprehensive surface functionalization strategies and efficient antibody conjugation technologies to meet diverse ADC system development needs.
BOC Sciences provides a variety of surface modification techniques to enhance nanocarrier stability, targeting ability, and functional integration:
Multiple efficient antibody conjugation methods are provided to ensure binding efficiency and antibody activity:
Site-specific modification and engineered antibody strategies are employed to maintain structural and functional integrity:
Supports the construction of complex ADC systems for combination targeting and synergistic therapy:
To ensure the quality and functional performance of nano-antibody-drug conjugates (nano-ADCs), BOC Sciences has established a comprehensive system for characterization and functional validation. Leveraging advanced analytical instrumentation and bioevaluation platforms, we systematically assess the key physicochemical properties of nanocarriers. In addition, we perform in vitro toxicity evaluations such as cellular uptake, subcellular localization, MTT, and IC₅₀ assays, extending to in vivo studies including pharmacokinetics, tissue distribution, and preliminary efficacy validation. These services comprehensively support quality control and preclinical evaluation of ADC development.
| Characterization Item | Technical Platform | Target Indicators |
| Particle Size Distribution | Dynamic Light Scattering (DLS) | Mean particle size, PDI |
| Surface Charge | Zeta Potential Analysis | Predict particle stability |
| Drug Encapsulation Efficiency | High-Performance Liquid Chromatography (HPLC) | >80% (customized based on target) |
| Antibody Conjugation Efficiency | SDS-PAGE, Mass Spectrometry | Controlled conjugation density |
| Stability Analysis | Storage Condition Testing | Physical and chemical stability assessment |
| Drug Release Behavior | Dialysis Method, pH-Sensitive Model | Controlled release profile |
At the project initiation stage, we offer nanocarrier type screening and custom design based on drug characteristics, target properties, and delivery strategy. Utilizing structural modeling, structure-activity relationship prediction, and database resources, we rapidly construct highly adaptable nanoplatform prototypes.
Through micro-scale trials and high-throughput screening, we optimize carrier particle size, loading efficiency, release behavior, and conjugation efficiency. We then establish a stable and reproducible preparation process, laying the groundwork for scale-up. Our platform supports various formulation systems including liposomes, polymeric nanoparticles, and inorganic particles.
Based on project requirements, we achieve site-specific or density-controlled conjugation of nanocarriers with antibodies. Multiple conjugation strategies are supported (e.g., maleimide, click chemistry, enzymatic ligation), along with PEGylation or functional group modifications to enhance targeting and in vivo stability.
BOC Sciences offers a comprehensive nano-characterization platform, including analysis of particle size, charge, morphology, conjugation efficiency, and release kinetics. We also conduct in vitro functional validation assays such as cellular uptake, target binding, and intracellular trafficking.
For successfully validated nano-ADC systems, we offer pilot scale-up services and establish control schemes for critical process parameters (CPP) and critical quality attributes (CQA), ensuring smooth transition from laboratory to GMP manufacturing environments.
BOC Sciences is well-versed in global biologics regulatory requirements. We assist clients with IND preparation and CMC documentation, supporting GMP-grade raw material preparation, carrier filling, and terminal sterile processing in an integrated production workflow to accelerate product launch.
We offer development of various nanocarrier types, including liposomes, polymeric nanoparticles, metallic nanoparticles, and lipid-polymer hybrid systems to meet the stability, release rate, and targeting requirements of different ADC drugs.
Yes. We support multiple conjugation strategies including covalent, non-covalent, enzymatic, and click chemistry, and can perform directional modifications (e.g., Fc region site-specific conjugation) to ensure antibody functionality and targeting precision.
Yes. We can incorporate pH-sensitive linkers, reduction-responsive structures, or enzyme-cleavable modules into nanocarriers to enable selective toxin release in the tumor microenvironment.
Yes. Equipped with ELISA, flow cytometry, SDS-PAGE, and other analytical tools, we can accurately assess antibody activity retention and conjugation efficiency to ensure the functional integrity of the formulation.
We provide full-scale biological validation services from cellular assays (e.g., MTT, IC₅₀, cellular uptake, intracellular localization) to animal-level pharmacokinetics, distribution, and preliminary efficacy evaluations.
Yes. We provide detailed reports including particle size, Zeta potential, morphology analysis, encapsulation efficiency, release profile, conjugation efficiency, and stability data to ensure traceable and controllable product quality.
Absolutely. We accept client-supplied antibodies, toxins, or nanoplatform materials and offer customized development and conjugation services based on your project goals.
